Table of Contents

• What is Timolol Maleate?
• Uses of Timolol Maleate
• How Timolol Maleate Works
• Forms and Administration
• Effectiveness
• Side Effects and Safety
• Ongoing Research

What is Timolol Maleate?

Timolol Maleate is a medication that belongs to a class of drugs called beta-blockers. It’s primarily used to treat eye conditions, but researchers are also exploring its potential in treating other medical issues. Timolol Maleate is known by several other names, including Timoptic, Timolol, and simply Timolol maleate^[1].

Uses of Timolol Maleate

Timolol Maleate is used to treat several conditions:

• Glaucoma: It’s primarily used to treat open-angle glaucoma, a condition where pressure inside the eye is too high, which can damage the optic nerve and lead to vision loss^[2].
• Ocular Hypertension: This is a condition where the pressure inside the eye is higher than normal, but hasn’t yet caused optic nerve damage^[2].
• Infantile Hemangioma: Some studies are exploring the use of Timolol Maleate to treat infantile hemangioma, which are benign (non-cancerous) growths of blood vessels that appear as red marks on infants’ skin^[3].
• Chronic Wounds: Researchers are investigating whether Timolol Maleate can help heal chronic wounds, such as diabetic foot ulcers or pressure sores^[4].

How Timolol Maleate Works

Timolol Maleate works by blocking certain receptors in the body called beta receptors. In the eye, this action helps to reduce the production of fluid (aqueous humor) inside the eye, which in turn lowers the pressure inside the eye. This is particularly important in treating glaucoma and ocular hypertension^[5].

Forms and Administration

Timolol Maleate comes in several forms:

• Eye Drops: This is the most common form for treating eye conditions. It’s usually available as a 0.5% solution^[1].
• Gel-Forming Solution: This form turns into a gel when it contacts the eye, which may help the medication stay in the eye longer^[6].
• Topical Gel: For treating conditions like infantile hemangioma, Timolol Maleate may be applied as a gel directly to the skin^[3].

The frequency of administration depends on the condition being treated and the form of the medication. For eye conditions, it’s typically used once or twice daily^[2].

Effectiveness

Timolol Maleate has been shown to be effective in lowering intraocular pressure (pressure inside the eye) in patients with glaucoma or ocular hypertension. In one study, patients using Timolol Maleate experienced a significant reduction in eye pressure after 8 weeks of treatment^[7].

For infantile hemangioma, early research suggests that Timolol Maleate may help reduce the size and color of these skin growths, although more studies are needed to confirm its effectiveness^[3].

Side Effects and Safety

Like all medications, Timolol Maleate can cause side effects. When used as eye drops, some common side effects may include:

• Stinging or burning sensation in the eyes
• Blurred vision
• Eye redness
• Tearing
• Light sensitivity^[2]

When absorbed into the bloodstream, Timolol Maleate can potentially affect other parts of the body. Researchers are studying how much of the drug enters the bloodstream when applied to the eye or skin, to ensure it’s safe for long-term use^[4].

Ongoing Research

Scientists continue to study Timolol Maleate to understand its full potential and ensure its safety. Some areas of ongoing research include:

• Comparing different formulations of Timolol Maleate to see which is most comfortable for patients^[1].
• Investigating its use in treating infantile hemangioma, including determining the optimal dosage and application method^[3].
• Exploring its potential in healing chronic wounds^[4].
• Studying how it interacts with other medications, such as antidepressants^[8].

These studies aim to improve our understanding of Timolol Maleate and potentially expand its uses in treating various medical conditions.

Table of contents

• Trial overview
• Who the trial is for
• What the study is testing
• Trial phase and design
• What researchers are measuring
• Study status and size

Trial overview

The available trial data shows one interventional study of XELAFASLATIDE in atrophic age-related macular degeneration (AMD), which is a form of eye disease that can damage central vision.^[1]

The study is designed to evaluate whether XELAFASLATIDE can slow the progression of disease in patients with geographic atrophy (GA) associated with AMD.^[1]

Who the trial is for

This trial targets people who have atrophic AMD, with the brief summary specifically naming patients with geographic atrophy linked to AMD.^[1]

The source data does not list the full inclusion or exclusion rules, so we only know the main condition being studied from the trial record.^[1]

What the study is testing

The study compares XELAFASLATIDE with a sham injection, which means a fake procedure used to help show whether the real treatment has an effect.^[1]

The intervention is listed as an ophthalmic solution for intravitreal use, which means it is intended for use in the eye.^[1]

The trial summary says the goal is to evaluate efficacy, meaning whether the treatment helps slow the disease compared with the sham procedure.^[1]

Trial phase and design

This is a Phase 2 trial, which is a study stage that usually looks more closely at whether a treatment may work while continuing to monitor safety.^[1]

The study type is interventional, meaning the researchers assign a treatment and compare outcomes between groups.^[1]

What researchers are measuring

The main outcome is GA lesion area assessment.^[1]

This means the researchers measure the size of the geographic atrophy area in the retina to see whether the disease is progressing more slowly.^[1]

Study status and size

The trial status is listed as Authorised.^[1]

The planned enrollment is 324 participants, which gives the study a moderate size for a Phase 2 trial.^[1]

Only one trial record was provided, so the article is based on that single study of XELAFASLATIDE.^[1]

The research involves children aged 6 to 14 years who have myopia of at least -1.50 diopters (a unit of measurement for the focusing power of the eye). During the study, participants will receive brimonidine eye drops, and their eye measurements will be taken every six months to track any changes in their vision. These measurements include the axial length (the distance from the front to the back of the eye), visual acuity (sharpness of vision), and other eye characteristics.

The study will monitor various aspects of eye health including pupillometry (measurement of pupil size under different lighting conditions), accommodation (how well the eye adjusts focus), corneal topography (mapping the surface curvature of the cornea), and intraocular pressure (pressure inside the eye). Throughout the study, safety will be assessed by collecting information about any adverse events.